Cooper Companies (NASDAQ:COO) Price Target Lowered to $92.00 at BNP Paribas Exane

Cooper Companies (NASDAQ:COO) had its price objective decreased by BNP Paribas Exane from $95.00 to $92.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “outperform” rating on the medical device company’s stock. BNP Paribas Exane’s price target suggests a potential upside of 36.09% from the stock’s current price.

Other analysts also recently issued research reports about the company. Stifel Nicolaus reduced their price objective on Cooper Companies from $95.00 to $85.00 and set a “buy” rating for the company in a research report on Friday. Needham & Company LLC reduced their price target on shares of Cooper Companies from $101.00 to $86.00 and set a “buy” rating on the stock in a research report on Friday. Rothschild & Co Redburn cut Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 target price on the stock. in a report on Wednesday, March 4th. KeyCorp reissued a “sector weight” rating on shares of Cooper Companies in a report on Friday. Finally, Wells Fargo & Company reiterated a “sell” rating and issued a $66.00 price objective (down from $82.00) on shares of Cooper Companies in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Cooper Companies currently has a consensus rating of “Hold” and an average target price of $82.64.

Cooper Companies Stock Performance

COO traded up $0.26 during trading on Monday, hitting $67.60. The stock had a trading volume of 3,020,908 shares, compared to its average volume of 2,299,306. The company has a current ratio of 1.27, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23. Cooper Companies has a 12 month low of $58.89 and a 12 month high of $89.83. The company has a 50 day simple moving average of $65.09 and a 200-day simple moving average of $74.54. The firm has a market cap of $13.19 billion, a PE ratio of 57.24, a P/E/G ratio of 1.73 and a beta of 0.87.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.11. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The firm’s revenue for the quarter was up 7.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.96 EPS. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. Analysts expect that Cooper Companies will post 4.63 EPS for the current year.

Institutional Trading of Cooper Companies

A number of institutional investors have recently modified their holdings of COO. Root Financial Partners LLC lifted its position in Cooper Companies by 104.5% during the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after buying an additional 162 shares in the last quarter. SJS Investment Consulting Inc. boosted its holdings in shares of Cooper Companies by 107.5% during the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock worth $26,000 after acquiring an additional 187 shares during the period. Bell Investment Advisors Inc boosted its stake in Cooper Companies by 106.3% in the 3rd quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 219 shares during the period. CYBER HORNET ETFs LLC acquired a new position in shares of Cooper Companies in the second quarter valued at about $36,000. Finally, True Wealth Design LLC grew its position in shares of Cooper Companies by 484.8% during the 4th quarter. True Wealth Design LLC now owns 462 shares of the medical device company’s stock worth $38,000 after purchasing an additional 383 shares in the last quarter. 24.39% of the stock is currently owned by institutional investors.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.